

Product Datasheet

A-1210477

Catalog No. **BP-02334** · CAS **1668553-26-1** · Form **free base** · Physical state **solid** · Color **white to off-white** · Version **1.0** · Revision **2026-09-10**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target Bcl-2 Family; Apoptosis	Research area Cancer
--	--------------------------------

Molecular formula **C₄₆H₅₅N₇O₇S**

Molecular weight **850.0370**

STRUCTURE



DESCRIPTION

A-1210477 is a potent and selective inhibitor of MCL-1 with a K_i of 0.45 nM. A-1210477 specifically binds MCL-1 and promotes apoptosis of cancer cells in an MCL-1-dependent manner.

BIOLOGICAL ACTIVITY

A-1210477 causes a dose-dependent reduction in the amount of BIM co-immunoprecipitated with MCL-1, with an IC_{50} in the low- μ M range. A-1210477 inhibits MCL-1-NOXA interactions with an IC_{50} of approximately 1 μ M, while having no effect on BCL-2-BIM or BCL-XL-BCL-XS interactions measured in the same cell background. A-1210477 binds to MCL-1 selectively and with sufficient affinity to disrupt MCL-1-BIM complexes in living cells. A-1210477 induces the hallmarks of intrinsic apoptosis and demonstrates single agent killing of multiple myeloma and non-small cell lung cancer cell lines demonstrated to be MCL-1 dependent by BH3 profiling or siRNA rescue experiments.

SOLUBILITY

Soluble in DMSO

REFERENCES

- [1]. Leveson JD, et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). *Cell Death Dis.* 2015 Jan 15;6:e1590.
- [2]. Qing Wang, et al. A-1210477, a selective MCL-1 inhibitor, overcomes ABT-737 resistance in AML. *Oncol Lett.* 2019 Nov;18(5):5481-5489.